GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (STU:19KA) » Definitions » Cyclically Adjusted Price-to-FCF

Cormedix (STU:19KA) Cyclically Adjusted Price-to-FCF : (As of Jun. 10, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cormedix Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cormedix Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cormedix's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Cyclically Adjusted Price-to-FCF Chart

Cormedix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cormedix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cormedix's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Cormedix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cormedix's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cormedix's Cyclically Adjusted Price-to-FCF falls into.



Cormedix Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cormedix's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cormedix's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.278/131.7762*131.7762
=-0.278

Current CPI (Mar. 2024) = 131.7762.

Cormedix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.218 100.560 -0.286
201409 -0.318 100.428 -0.417
201412 -0.287 99.070 -0.382
201503 -0.456 99.621 -0.603
201506 -0.507 100.684 -0.664
201509 -0.379 100.392 -0.497
201512 -0.475 99.792 -0.627
201603 -0.680 100.470 -0.892
201606 -0.460 101.688 -0.596
201609 -0.747 101.861 -0.966
201612 -0.762 101.863 -0.986
201703 -0.778 102.862 -0.997
201706 -0.656 103.349 -0.836
201709 -0.475 104.136 -0.601
201712 -0.468 104.011 -0.593
201803 -0.382 105.290 -0.478
201806 -0.225 106.317 -0.279
201809 -0.233 106.507 -0.288
201812 -0.302 105.998 -0.375
201903 -0.283 107.251 -0.348
201906 0.006 108.070 0.007
201909 -0.150 108.329 -0.182
201912 -0.136 108.420 -0.165
202003 -0.277 108.902 -0.335
202006 -0.026 108.767 -0.032
202009 -0.210 109.815 -0.252
202012 -0.152 109.897 -0.182
202103 -0.155 111.754 -0.183
202106 -0.068 114.631 -0.078
202109 -0.140 115.734 -0.159
202112 -0.151 117.630 -0.169
202203 -0.160 121.301 -0.174
202206 -0.130 125.017 -0.137
202209 -0.149 125.227 -0.157
202212 -0.142 125.222 -0.149
202303 -0.220 127.348 -0.228
202306 -0.175 128.729 -0.179
202309 -0.144 129.860 -0.146
202312 -0.176 129.419 -0.179
202403 -0.278 131.776 -0.278

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cormedix  (STU:19KA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cormedix Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cormedix's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cormedix (STU:19KA) Business Description

Industry
Traded in Other Exchanges
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

Cormedix (STU:19KA) Headlines

No Headlines